Subscribe
Conference Correspondent

Daratumumab: What Patients Want to Know

Conference Correspondent, ASH
Conference Correspondent 
Leslie Lauersdorf addresses the different questions her patients ask her when they begin daratumumab therapy.

Related Items

Single-Drug Targeted Therapy May Improve Proportion of Patients With Hard-to-Treat Leukemias Proceeding to Transplant
By Wayne Kuznar
TON - February 2024 Vol 17, No 1
Leukemia, ASH
Isatuximab plus RVd Achieves Highest Rates of No MRD in Multiple Myeloma
By William King
TON - April 2022 Vol 15, No 2
ASH, Hematologic Malignancies
Addition of Ivosidenib to Azacitidine Improves Outcomes for Patients with AML and IDH1 Mutation
By Patricia Stewart
TON - April 2022 Vol 15, No 2
ASH
POLARIX Trial Results Support Use of Polatuzumab Vedotin plus R-CHP as Frontline Treatment for DLBCL
By Patricia Stewart
TON - April 2022 Vol 15, No 2
ASH
Circulating Tumor DNA Profiling May Allow for Better Detection and Treatment of CNS Lymphoma
By Patricia Stewart
TON - April 2022 Vol 15, No 2
ASH
CAR T-Cell Therapies May Improve Outcomes in Relapsed/Refractory Large B-Cell Lymphoma
TON - February 2022 Vol 15, No 1
ASH, Lymphoma
Studies Shed New Light on Antibody Responses to COVID-19 Vaccines in Patients with Hematologic Diseases
TON - February 2022 Vol 15, No 1
ASH
Mosunetuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Follicular Lymphoma
TON - February 2022 Vol 15, No 1
ASH
What is Minimal Residual Disease (MRD) Negativity?
By Leslie Lauersdorf, ARNP
Videos
ASH 2019 MM, Multiple Myeloma, Video
Multiple Myeloma as a Chronic Disease
By Leslie Lauersdorf, ARNP
Videos
ASH 2019 MM, Multiple Myeloma, Video

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.